Presentations

RP2 Alone and with Nivolumab in Patients with Advanced Solid Tumors from the Phase 1 FIH Study at ASCO 2026

May 31, 2026

RP1+ Nivolumab in Patients with Anti-PD-1-Failed Melanoma from the IGNYTE trial at ASCO 2026

May 30, 2026

RP1 + Nivolumab in Patients with NMSC at EADO 2026

April 23, 2026

RP1 + Nivolumab in Patients with Anti–PD-1–Failed Melanoma at EADO 2026

April 23, 2026

Journal for ImmunoTherapy of Cancer: Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon

March 3, 2026

Replimune JP Morgan Healthcare Conference 2026 Presentation

January 14, 2026

Journal of Clinical Oncology: RP1 Combined With Nivolumab in Advanced Anti–PD-1– Failed Melanoma (IGNYTE)

November 30, 2025

RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Melanoma at SITC 2025

November 7, 2025

RP1 + Nivolumab in Patients with and without prior BRAF-Directed Therapy at SITC 2025

November 7, 2025

IGNYTE Trial Biomarker and Updated Clinical Data Presentation at SITC 2025

November 7, 2025